Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | AR | P10275 | 3/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13029712 | 0.95 | CNR2 (0.38) | CNR2ARCNR1CRHR1ESR1 | |
| SCHEMBL13029695 | 0.91 | CNR2 (0.40) | CNR2ARCNR1CRHR1 | |
| SCHEMBL13029701 | 0.89 | AR (0.37) | CNR2ARCNR1CRHR1CYP3A4 | |
| SCHEMBL13029685 | 0.89 | CNR2 (0.41) | CNR2ARCNR1CRHR1 | |
| SCHEMBL13029702 | 0.88 | CNR2 (0.38) | CNR2ARCNR1CRHR1LMNA | |
| SCHEMBL13029711 | 0.86 | CNR2 (0.39) | CNR2ARCNR1CRHR1SLC6A2 | |
| SCHEMBL13029742 | 0.85 | AR (0.33) | ARESR1ESR2CYP3A4 | |
| SCHEMBL13029693 | 0.84 | ALDH1A1 (0.41) | CNR2ARCNR1LMNA | |
| SCHEMBL13029713 | 0.84 | AR (0.36) | CNR2ARCNR1CRHR1 | |
| SCHEMBL13029710 | 0.84 | CNR2 (0.40) | CNR2ARCNR1CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834063-B2 | 4-[(Cyclopropylmethyl)(2-{[4-(1,1-dimethylethyl)phenyl]oxy}ethyl)amino]-2-(trifluoromethyl)benzonitrile; modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors; osteoporosis, muscle wasting,endometriosis, cardiovascular disease; breast, uterine cancer, prostatic hyperplasia | GLAXOSMITHKLINE LLC (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080255124-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255124-A1 | Chemical Compounds | NR3C2, NR5A1, NR3C1 | CNR2 528/4885AR 4/4885CNR1 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.